N/A N=12 Treatment

Study of Tarceva and Targretin in Stage I-II Lung Cancer

Carcinoma, Non-small-cell Lung

Bottom Line

View on ClinicalTrials.gov: NCT00125372 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2018

Primary outcome: Primary: Number of Participants With Change in Expression Level of EGFR. — 3; 7 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: erlotinib (Tarceva) and bexarotene (Targretin) (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Dartmouth-Hitchcock Medical Center
Primary completion: Aug 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With Change in Expression Level of EGFR.	3; 7	—
PRIMARY Number of Participants With Change in Expression Level of Cyclin D1	6; 4	—
PRIMARY Number of Participants With Change in Expression Level of Phosphorylated EGFR (pEGFR)	6; 4	—
SECONDARY Tumor Tissue Concentrations of Erlotinib and Bexarotene and Correlation With Plasma Levels	—	—
SECONDARY Number of Participants With EGFR Mutations and Correlation of EGFR Mutations With Response	4; 4; 1; 0; 0; 1	—

Summary

The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.

Eligibility Criteria

Inclusion Criteria

Resectable stage I or II non-small-cell lung cancer
Prior tissue biopsy (not cytology) available for research analysis
Adequate hepatic and renal function

Exclusion Criteria

Prior chemotherapy or radiotherapy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00125372). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.